|
Market Closed -
Nasdaq
21:00:00 14/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 60.99 USD | +2.49% |
|
+4.36% | +39.15% |
| 10-09 | Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says | MT |
| 10-09 | RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | +2.49% | +4.36% | +39.15% | +54.37% | +179.26% | 14.75B |  | | |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
